A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Vitiligo, Non-Segmental Vitiligo (NSV)

In brief

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Key facts

Study ID

NCT07533019

Run by

Eli Lilly and Company

People needed

66

Starts

2026-04-14

Expected to finish

2027-09-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible participants must have the following at both screening and baseline:
• A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
• Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
• BSA involvement of ≥0.5% on the face
• F-VASI ≥0.5 and T-VASI ≥3, and
• Either active or stable disease at both screening and baseline

You may not qualify if…

• Participants who have other types of vitiligo that are not considered active or stable vitiligo
• Currently have active forms of other disorders of pigmentation
• Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
• Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
• Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
• Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Where it is running

• Centrum Medyczne Ginemedica — Wroclaw, Poland (enrolling)
• Clinical Research Partners, LLC — Richmond, Virginia, United States (enrolling)
• Anima Diepenbeek — Diepenbeek, Belgium (enrolling)
• INTERMED Groupe Sante — Chicoutimi, Canada (enrolling)
• DermEffects — London, Canada (enrolling)
• Dar Clinical Research - Ottawa - Hunt Club Road — Ottawa, Canada (enrolling)
• Research Toronto — Toronto, Canada (enrolling)
• Centrum Badan Klinicznych PI-House sp. z o.o. — Gdansk, Poland (enrolling)
• Diamond Clinic — Krakow, Poland (enrolling)
• Dermedic Jacek Zdybski — Ostrowiec Świętokrzyski, Poland (enrolling)
• Medical Dermatology Specialists — Phoenix, Arizona, United States (enrolling)
• Center For Dermatology Clinical Research, Inc. — Fremont, California, United States (enrolling)
• Northridge Clinical Trials — Northridge, California, United States (enrolling)
• Cura Clinical Research - Oxnard — Oxnard, California, United States (enrolling)
• Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway — Santa Clarita, California, United States (enrolling)
• Health Clinical Research, LLC — Miami, Florida, United States (enrolling)
• K2 Medical Research - Tampa — Tampa, Florida, United States (enrolling)
• Advanced Medical Research, PC. — Sandy Springs, Georgia, United States (enrolling)
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States (enrolling)
• Revival Research Institute, LLC — Troy, Michigan, United States (enrolling)
• Stracskin — Portsmouth, New Hampshire, United States (enrolling)
• Equity Medical — The Bronx, New York, United States (enrolling)
• Accurate Clinical Research, Inc — Humble, Texas, United States (enrolling)
• Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue — San Antonio, Texas, United States (enrolling)
• Jordan Valley Dermatology & Research Center — South Jordan, Utah, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.